NLRP3 expression is of importance in preclinical models of MASLD, as a loss of function improves liver inflammation and a gain of function worsens liver disease and associated liver fibrosis [64]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.